Patent ID: 11857601
Assignee: GI INNOVATION, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 0:
1. A pharmaceutical composition comprising, as active ingredients, a fusion protein dimer comprising a CD80 fragment and an IL-2 variant; and an anticancer agent,
wherein the CD80 fragment is an extracellular domain of CD80 protein;
wherein the IL-2 variant comprises the amino acid sequence of SEQ ID NO: 10 with substitutions of R38A and F42A;
wherein the fusion protein has the following structural formula (I) or (II):

N′-X-[linker(1)]n-Fc domain-[linker(2)]m-Y-C′  (I)

N′-Y-[linker(1)]n-Fc domain-[linker(2)]m-X-C′  (II)

in the structural formulas (I) and (II),
N′ is the N-terminus of the fusion protein,
C′ is the C-terminus of the fusion protein,
X is the extracellular domain of CD80 protein,
Y is the IL-2 variant comprising the amino acid sequence of SEQ ID NO: 10 with substitutions of R38A and F42A,
the linkers (1) and (2) are peptide linkers, and
n and m are each independently 0 or 1,
and wherein the anticancer agent is selected form the group consisting of an anti-PD-1 (programmed cell death protein 1) antibody, an anti-PD-L1 (programmed cell death ligand 1) antibody, an anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) antibody, a VEGFR (vascular endothelial growth factor receptor) inhibitor, an EGFR (epidermal growth factor receptor) inhibitor, a PARP (poly (ADP-ribose) polymerase) inhibitor, a DNA methyltransferase inhibitor, a TGF-β (Transforming growth factor beta) receptor inhibitor, a CDK4/6 (cyclin-dependent kinase 4 and 6) inhibitor, a STING (stimulator of interferon genes) agonist, an alkylating agent, a microtubule inhibitor, an antimetabolite, a topoisomerase inhibitor, and combinations thereof.